Елена Владимировна Артамонова
Pirogov Russian National Research Medical University · 229 works · 374 citations · h-index 7
Top works
- Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
- Adjuvant Fermented Wheat Germ Extract (Avemar ™ ) Nutraceutical Improves Survival of High-Risk Skin Melanoma Patients: A Randomized, Pilot, Phase II Clinical Study with a 7-Year Follow-Up
- Malignant neoplasm of the bronchi and lung: Russian clinical guidelines
- The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib
- Malignant neoplasm of the bronchi and lung: Russian clinical guidelines
- Практические рекомендации по лекарственному лечению рака прямой кишки
- Final results of a phase II trial of prolgolimab with platinum-based therapy and bevacizumab in patients with advanced cervical cancer.
- Efficacy of EDP ± mitotane chemotherapy in the treatment of metastatic adrenocortical carcinoma. Predictive and prognostic factors of efficacy
- Microsatellite instability (MSI) in patients with gastric cancer (GC) and correlation with PD-L1 expression.
- Neoadjuvant therapy for breast cancer. Value of residual disease
- 402P First-line ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without visceral crisis from the phase II RIGHT choice study
- Clinical utility of scintigraphy and SPECT/CT with 99m Tc-Tectrotyd in patients with neuroendocrine tumors
- Myths about inexpediency of carrying out peptide receptor radionuclide diagnostics in patients with neuroendocrine tumors
- The consensus on the prevention and correction of rash in patients with HR+ HER2- metastatic breast cancer treated with alpelisib
- Trastuzumab deruxtecan (T-DXd) in pretreated patients (pts) with HER2-expressing bladder cancer: Final results from the bladder cancer cohort in Part 1 of DESTINY-PanTumor02 (DP-02).
- Tumor-Infiltrating Lymphocytes in Breast Cancer. Association with Clinical and Pathological Parameters
- Treatment tactics of new NET G3 subgroup in first line of therapy
- Практические рекомендации по лекарственному лечению немелкоклеточного рака легкого
- Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia
- Dual HER2 blockade with pertuzumab+trastuzumab on the eve of a new era in the treatment of HER2-positive breast cancer